Physician profile
Farid Razavi
NPI 1407099112
$119,288.98
in general payments reported to CMS, 2019-2025
40 companies · $13K in 2025
The $13K reported for 2025 was more than what 94% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,420 · 2020: $6,503 · 2021: $8,883 · 2022: $17K · 2023: $7,201 · 2024: $62K · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $65K · Travel and Lodging: $9,209 · Food and Beverage: $8,261 · Education: $30.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $65,025.00 |
| Travel and Lodging | $9,209.26 |
| Food and Beverage | $8,260.66 |
| Education | $30.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $53,366.38 | 2024-2025 | Voquezna |
| Abbvie INC. | $45,090.02 | 2019-2025 | |
| Biohorizons Implant Systems INC. | $11,250.00 | 2022 | |
| Allergan, INC. | $3,236.45 | 2019 | |
| Janssen Biotech, INC. | $1,286.04 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Celgene Corporation | $641.18 | 2021-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $601.50 | 2019-2025 | Xifaxan |
| Pfizer INC. | $479.33 | 2019-2025 | |
| Genzyme Corporation | $463.65 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $405.55 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Ardelyx, INC. | $265.52 | 2023-2025 | Ibsrela |
| Lilly USA, LLC | $241.82 | 2024-2025 | Omvoh |
| Madrigal Pharmaceuticals | $205.15 | 2024-2025 | Rezdiffra, Resmetirom |
| Gilead Sciences, INC. | $200.89 | 2019-2022 | |
| Intercept Pharmaceuticals, INC. | $180.27 | 2019-2024 | Ocaliva |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic USA, INC. | $162.96 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $130.87 | 2024-2025 | Iqirvo |
| Ironwood Pharmaceuticals, INC | $114.79 | 2019-2024 | Linzess |
| Qol Medical, LLC | $109.13 | 2022-2023 | Sucraid |
| Amgen INC. | $106.26 | 2025 | Uplizna |
| Ferring Pharmaceuticals INC. | $82.18 | 2021-2023 | Rebyota |
| Orphalan INC | $77.80 | 2024-2025 | Cuvrior |
| Daiichi Sankyo INC. | $74.02 | 2019-2024 | Injectafer |
| Nestle Healthcare Nutrition INC. | $54.95 | 2021-2023 | |
| Regeneron Healthcare Solutions, INC. | $54.62 | 2022-2023 | Dupixent |
| Redhill Biopharma INC. | $38.80 | 2021 | |
| Ucb, INC. | $37.24 | 2019-2020 | |
| Medtronic, INC. | $35.82 | 2021-2024 | Interstim |
| Digestive Care, INC. | $33.78 | 2024 | Pertzye |
| Endo Pharmaceuticals INC. | $33.46 | 2019 | |
| Shionogi INC | $32.90 | 2019 | |
| Aimmune Therapeutics, INC. | $29.74 | 2024-2025 | Zenpep |
| Braintree Laboratories, INC. | $27.47 | 2022 | |
| Merck Sharp & Dohme LLC | $25.50 | 2020-2024 | Dificid, Zerbaxa |
| Alexion Pharmaceuticals, INC. | $24.61 | 2023 | |
| Micro-Tech Endoscopy USA, INC. | $23.62 | 2024 | Rapide Balloons |
| Mallinckrodt Hospital Products INC. | $23.59 | 2024 | Terlivaz |
| E.R. Squibb & Sons, L.L.C. | $21.79 | 2024 | Zeposia |
| Novo Nordisk INC | $19.33 | 2025 | Wegovy |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$66,181.88 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Farid Razavi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.